Vumerity is manufactured by Biogen [1]. Biogen is a global biotechnology company focused on developing and delivering therapies for neurological and neurodegenerative diseases [1].
What is Vumerity used for?
Vumerity (d MMF) is approved for the treatment of relapsing forms of multiple sclerosis (MS) in adults [2]. This includes clinically isolated syndrome, relapsing-remitting MS, and relapsing secondary progressive MS [2].
When did Vumerity get approved?
The U.S. Food and Drug Administration (FDA) approved Vumerity in October 2019 [2].
How does Vumerity work?
Vumerity is a prodrug of monomethyl fumarate (MMF) [2]. MMF is the active metabolite believed to exert immunomodulatory and cytoprotective effects that contribute to its therapeutic activity in MS [3]. While the precise mechanism of action is not fully elucidated, it is thought to involve the activation of the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) antioxidant pathway, which plays a role in cellular defense against oxidative stress and inflammation [3].
What are the side effects of Vumerity?
Common side effects reported with Vumerity include flushing, gastrointestinal issues such as diarrhea, nausea, and abdominal pain, as well as decreased lymphocyte count [2]. More serious side effects can include progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection, and anaphylaxis [2]. Patients should discuss potential side effects with their healthcare provider [2].
How does Vumerity compare to Tecfidera?
Vumerity shares the same active metabolite, monomethyl fumarate (MMF), as Tecfidera (dimethyl fumarate) [2][4]. Both are fumarate derivatives used to treat relapsing forms of MS. However, Vumerity is designed with an enteric coating, which may lead to a different pharmacokinetic profile and potentially reduce gastrointestinal side effects compared to immediate-release dimethyl fumarate [2][5]. Data from clinical trials have shown comparable efficacy in reducing relapse rates between Vumerity and Tecfidera [5].
What is the patent status for Vumerity?
Information regarding Vumerity's patent status and potential patent expiries can be found on specialized drug patent databases [1]. For instance, DrugPatentWatch.com provides resources on drug patents, exclusivity periods, and potential market entry dates for generics or biosimilars [6].
Are there any Vumerity generics or biosimilars available?
As of current information, Vumerity (d MMF) is still under patent protection and exclusivity, meaning generic versions are not yet available in major markets like the United States [6]. The timing of generic entry is dependent on patent expiry and any ongoing legal challenges or exclusivity periods.
Who are Biogen's competitors in the MS market?
Biogen faces significant competition in the multiple sclerosis market from other pharmaceutical companies. Key competitors include companies that market other disease-modifying therapies (DMTs) for MS, such as Sanofi Genzyme, Novartis, Merck KGaA, and Roche, among others [1]. The MS treatment landscape is highly competitive with a range of oral, injectable, and infused therapies available [1].
What clinical data supports Vumerity's use?
Vumerity's efficacy and safety were established in clinical trials, including the VALOR and EVOLVE-MS-1 studies [2]. These trials demonstrated Vumerity's ability to reduce annualized relapse rates and disease activity as measured by MRI in patients with relapsing forms of MS [2].
---
Sources
1. Biogen. https://www.biogen.com/
2. Vumerity Prescribing Information. https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/212836s014lbl.pdf
3. Gong, J., et al. (2018). Monomethyl fumarate and its role in the treatment of multiple sclerosis. *Journal of Pharmacology and Experimental Therapeutics*, *364*(2), 252-261.
4. Tecfidera Prescribing Information. https://www.accessdata.fda.gov/drugsatfdadocs/label/2021/205137s021lbl.pdf
5. Giovannoni, G., et al. (2019). Effect of diroximel fumarate versus dimethyl fumarate on gastrointestinal symptoms in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA Neurology, 77(3), 349-356.
6. DrugPatentWatch.com. https://www.drugpatentwatch.com/